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Vascular access stenosis is a major complication in hemodialysis patients. We prospectively observed 50 patients in whom 50
nitinol shape-memory alloy-recoverable technology (SMART) stents were used as salvage therapy for recurrent peripheral venous
stenosis. Twenty-ﬁve stents each were deployed in native arteriovenous ﬁstula (AVF) and synthetic arteriovenous polyurethane
graft (AVG) cases. Vascular access patency rates were calculated by Kaplan-Meier analysis. The primary patency rates in AVF
versus AVG at 3, 6, and 12 months were 80.3% versus 75.6%, 64.9% versus 28.3%, and 32.3% versus 18.9%, respectively. The
secondary patency rates in AVF versus AVG at 3, 6, and 12 months were 88.5% versus 75.5%, 82.6% versus 61.8%, and 74.4% versus
61.8%, respectively. Although there were no statistically signiﬁcant diﬀerence in patency between AVF and AVG, AVG showed poor
tendency in primary and secondary patency. The usefulness of SMART stents was limited in a short period of time in hemodialysis
patients with recurrent vascular access stenosis.
1.Introduction
Although percutaneous transluminal angioplasty (PTA) is
the standard for treatment of vascular access venous stenosis
and occlusion since the 1980s [1], it carries a high rate
of restenosis, and repeated endovascular intervention is
often necessary. Compared with native arteriovenous ﬁstula
(AVF), synthetic arteriovenous grafts (AVG) are associated
withmuchhigherratesoffailureandintervention becauseof
the increased rates of stenosis/thrombosis. The intervention
rates for AVG are reported to be about ﬁve times higher
than those for AVF, with patency rates less than 50% at 3
years [2]. To improve these statistics, various indications for
the use of endovascular stents have been studied since 1989
[3], including elastic recoil [4–6], rapid recurrence [7], and
venous rupture after PTA [8].
Although endovascular stent placement is one of the
standard treatments in percutaneous coronary and periph-
eral artery disease, its role in the treatment of vascular
access stenosis remains controversial. Early studies reported
that routine use of metallic stents failed to provide any
additional beneﬁt when compared with PTA alone [3].
Multiple studies have compared endovascular stents to PTA
in terms of patency, but most of references reported limited
or no advantages to a stent placement for peripheral venous
and graft stenoses [2, 4, 9–13]. Cohort study conducted by
Vogel and Parise reported that nitinol shape-memory alloy-
recoverable technology (SMART) stents improved primary2 International Journal of Nephrology
and secondary graft patency in AVG cases [14]. Recent
publications have reported that covered stents or stent-graft
placement was not inferior in patency to PTA alone [15–17].
Therefore, the exact role and indications of stent placement
in the treatment of stenotic lesions in AVF and AVG remain
unclear.
In this study, we prospectively observed 50 patients in
whom 50 SMART stents were used as salvage therapy for
recurrent peripheral venous stenosis and compared patency
between AVF and AVG in cases of post-PTA failure caused by
elastic recoil and rapidly recurrent stenosis.
2. Patientsand Methods
2.1. Study Population. This study was approved by the in-
stitutional ethical committee of Oyokyo Kidney Research
Institute. Informed consent was obtained from all patients.
From June 2009 to September 2010, 548 patients underwent
hemodialysis at the Oyokyo Kidney Research Institute in
Hirosaki, Japan. During that period, total 453 PTAs were
performed and all endovascular procedures were performed
by the well-trained interventional urologists in this institute.
We followed up consecutive 50 patients who underwent
SMART stent placement as salvage therapy for recurrent
peripheral venous stenosis. Twenty-ﬁve stents each were
deployed in native AVF and synthetic AVG.
2.2. Inclusion and Exclusion Criteria. Inclusion criteria were
(1) age of 18 to 90yr and a hemodialysis access consisting of
anAVForanAVGlocatedinthearm,(2)stablehemodialysis
sessions were performed, (3) color Doppler ultrasonography
or angiographic evidence of 1 or more stenotic lesion,
7cm or less in length, and 50% or more stenosis com-
pared with previous evaluation, (4) diﬃcult vascular access;
percutaneous endovascular therapy was thought to be the
best treatment choice for the identiﬁed lesion because it is
diﬃcult to develop new vascular accesses in other lesions,
(5) recoil and/or kinked venous stenosis within the past 3
months, (6) more than 3 time of PTA history, (7) Eastern
Cooperative Oncology Group Performance Status (ECOG
PS) [18] grade 0 to 4. In this study, poor general health
(ECOG PS > 2), major concomitant disease (e.g., terminal
cancer), or other medical condition likely to result in death
within 6 months after the time of implantation were not
in exclusion criteria. Exclusion criteria were (1) recurrent
stenosis with a corresponding thrombosis treated within 7
days before enrollment, (2) a blood coagulation disorder
or sepsis, (3) a contraindication to the use of contrast
medium,(4)infectedarteriovenousaccessgraft,(5)presence
of an alternate stent, (6) stenotic lesion which needed more
than 6mm diameter stent in upper-arm outﬂow vein or
subclavian vein, and (7) occluded vascular access.
2.3. Technical Description. AVF and AVG were initially can-
nulated with a 16–18-gauge puncture needle, and a 6-French
catheter sheath was inserted over a guide wire into the lumen
of AVF or AVG. Diluted contrast media was injected for
digital subtraction angiography to localize stenotic lesions.
An angioplasty balloon (Conquest, 6mm in diameter, 25–30
atmospheres in pressure; BARD Inc., Murray Hill, NJ, USA
or LUMEFA, 6mm in diameter, 18 atmospheres in pressure;
Toray Medical Co., Chiba, Japan) was placed and inﬂated
at the level of the stenotic site. If severe elastic recoil or
signiﬁcant residual stenosis was observed or if the stenosis
had recurred shortly after a previous intervention, a SMART
stent (SMART Control; Cordis/Johnson & Johnson, Warren,
NJ, USA) that was 6mm in diameter and 40–80mm in
length was deployed. All patients received 3000–4000U of
heparin during the procedure. Antiplatelet agents remained
unchanged in all patients before and after the intervention.
2.4. Follow-Up Protocol and Intervention Indications. For
blood accessfollowup,peripheral vascularstenosis wasmon-
itored by color Doppler ultrasonography every 1–3 months.
Catheter-based interventions were performed in patients
who met the clinical criteria for vascular access dysfunction
and had stenosis of more than 50%.
2.5.Evaluation.Primary(unassisted)andsecondary(assisted)
patency was calculated from the date of stent placement
to the ﬁrst subsequent intervention and permanent blood
access failure. Primary and secondary patency rates were
calculated using the Kaplan-Meier method and log-rank test.
2.6. Statistical Analysis. Statistical analyses were performed
using SPSS (SPSS Inc., ver. 12.0, Chicago, IL, USA) and
Microsoft Excel (Microsoft Co., Redmond, WA, USA)
programs. All values included in the ﬁgures and text are
expressed as means ± SD. Datasets were compared using the
Mann-Whitney’s U test or a paired t test. A P value of less
than 0.05 was considered to be signiﬁcant.
3. Results
Fifty SMART stents were deployed in cases of dysfunctional
blood access for salvage therapy in 50 patients. The median
number of follow-up days after SMART stent deployment
was290.PatientcharacteristicsareshowninTable 1.T wenty-
ﬁveSMARTstentseachweredeployedinAVFandAVGcases.
No diﬀerence was observed in patient backgrounds. Stent
location was signiﬁcantly diﬀerent between AVF and AVG
casesbecausemajorstenoticlesionswerelocatedinthelower
arm in AVF cases and in the upper arm in AVG cases.
To determine the eﬃcacy of SMART stent placement
for AVF and AVG, primary patency rates were evaluated
using the Kaplan-Meier method. The primary patency ratios
for AVF versus AVG at 3, 6, and 12 months were 80.3%
versus 75.6%, 64.9% versus 28.3%, and 32.3% versus 18.9%,
respectively (Table 2). The 50% access patency times were
230 days in AVF cases and 133 days in AVG cases. There was
nosigniﬁcantdiﬀerencebetweentheeﬃcacyofSMARTstent
placement in AVF and AVG cases (P = 0.1010), but inferior
in AVG at 6 and 12 months (64.9% versus 28.3% and 32.3%
versus 18.9%, resp.,) (Table 2, Figure 1).
The secondary patency rates for SMART stents at 3, 6,
and 12 months were 83.4%, 74.2%, and 68.0%, respectivelyInternational Journal of Nephrology 3
Table 1: Patient characteristics. Twenty-ﬁve SMART stents each were deployed in AVF and AVG cases. There was no signiﬁcant diﬀerence,
other than stent location, between the backgrounds of the patients in the two groups.
ALL AVF AVG P value
Number of patients 50 25 25
Number of stents 50 25 25
Age 71.6 ± 11.3 71.2 ± 11.3 72.2 ± 11.6 n.s.
Gender (M/F) 24/27 13/12 10/15 n.s.
Primary renal disease
DM 24 12 12 n.s.
non DM 26 13 13
Hemodialysis history (years) 7.3 ± 6.1 7.8 ± 6.2 6.6 ± 5.9 n.s.
PTA history (times) 4.6 ± 3.9 4.5 ± 3.5 4.8 ± 4.3 n.s.
Diﬃcult vascular access∗ 50 25 25
Poor general health∗∗ (%) 35 (70%) 18 (72%) 17 (68%) n.s.
Use of antiplatelet agents 49 24 25 n.s.
Stent location
Upper arm 22 4 18 0.0002
Lower arm 28 21 7
∗Diﬃcult vascular access; percutaneous endovascular therapy thought to have been the best treatment choice for the identiﬁed lesion because it is diﬃcult to
develop new vascular accesses in other lesions. ∗∗Poor general health; Eastern Cooperative Oncology Group Performance Status grade 3 or 4.
Table 2: Primary patency for SMART stent placement in AVF and AVG cases. There was no signiﬁcant diﬀerence in primary patency rates
between AVF and AVG cases, but patency in AVG showed inferior to AVF.
All AVF AVG P value
n 50 25 25
Primary patency (Days) 140 ± 105 168 ± 118 110 ± 78.9 0.0051
(range) (17–401) (17–401) (38–378)
Primary patency (%)
3 months 79 80.3 75.6
0.1010 6 months 51.3 64.9 28.3
12 months 27.1 32.3 18.9
(Table 3). Restenosis after stent placement occurred in 23
patients (46%). The reasons for primary patency failure were
in-stent stenosis (14/23, 61%), outﬂow stenosis (4/23, 17%),
and stenosis unrelated to stent placement (5/23, 22%). The
ratioofoutﬂowstenosisonsetwassigniﬁcantlyhigherinAVF
cases (P = 0.045). The secondary patency ratios of patients
with SMART stents did not signiﬁcantly diﬀer between AVF
and AVG (P = 0.1299), but inferior in AVG at 3, 6, and 12
month (88.5% versus 75.5%, 82.6% versus 61.8%, and 74.4%
versus 61.8%, resp.,) (Table 3, Figure 2).
Complications associated with SMART stent deploy-
ment were not observed. Episodes of symptomatic arterial
embolization of thrombus, signs of pulmonary embolism, or
stent infection during followup were not observed.
4. Discussion
The maintenance of vascular access in hemodialysis patients
is critical to the quality of life and survival. However, high
rates of restenosis and repeat endovascular intervention
associated with PTA remain problematic issues. Multiple
devices and techniques such as cutting balloon angioplasty
[19], metallic stents [12, 14], and more recently stent grafts
or covered stents [15] have been used. Metallic stents have
been used for blood access for more than 20 years [20], but
theeﬀectofmetallicstentsinperipheralvascularaccessisstill
controversial. Although there is some evidence that metallic
stentshavethepotentialtoalleviaterapidlyrecurringperiph-
eralvenousstenosis[7],useofmetallicstents(Wallstent)was
not recommended because a prospective, randomized trial
showednoadvantageofitsuseoverconventionalangioplasty
[11].
On the other hand, some studies supported the eﬃcacy
of metallic stent (SMART) placement for salvage angio-
plasty. A SMART stent is composed of nitinol, a nickel-
titanium metallic alloy with shape memory function. The
advantages of a SMART stent over conventional metallic
stents (Wallstent) include a high degree of strength and
superelasticity. Nitinol possesses a high degree of ﬂexibil-
ity and kink and fatigue resistance; these properties are
not aﬀected by repeated interventions. In addition, its
superelasticity ensures equal distribution of wall contact
and confers the ability to adapt to native vessel contours
more successfully than conventional stents. Vogel and Parise
reported improved performance using the nitinol stent,
demonstrating the eﬃcacy of SMART stent placement in4 International Journal of Nephrology
Table 3: Secondary patency for SMART stent placement in AVF and AVG cases.There was no signiﬁcant diﬀerence in secondary patency
rates between AVF and AVG cases, but patency in AVG showed inferior to AVF. The rate of outﬂow stenosis onset was signiﬁcantly higher in
AVF cases (P = 0.045).
All AVF AVG P value
n 50 25 25
Secondary patency (Days) 189 ± 129 224 ± 129 151 ± 121 n.s.
(range) (18–259) (18–241) (63–259)
Secondary patency (%)
3 months 83.4 88.5 75.5
6 months 74.2 82.6 61.8 0.1299
12 months 68 74.4 61.8
Reasons of primary patency failure
In-stent stenosis (%) 14 (28) 6 (24) 8 (32) n.s.
Out-ﬂow stenosis (%) 4 (8) 4 (16) 0 (0) 0.045
Others (%) 5 (10) 2 (8) 3 (12) n.s.
Table 4: Summary of recent reports of outcome using metallic stents. The 3-, 6-, and 12-month patency rates were 77–88%, 51–67%, and
20–41%, respectively.
Investigators Year n Study design Stent type AVF or AVG
Primary patency (%) (months)
3M 6M 12M
Vogel and Parise
[12] 2004 53 Retrospective SMART AVG 77 (61–93) 51 (34–67) 20 (12–27) mean 8.9
Vogel and Parise
[14] 2005 25
Prospective,
Non-
randomized
SMART AVG 88
(75–100) 67 (48–86) 41 (21–61) mean 8.2
Pan et al. [21] 2005 12 Retrospective Wallstent,
Jostent AVF 92 ± 88 1 ± 12 31 ± 17 n/a
Liang et al. [22] 2006 23 Observational Wallstent,
nitinol AVG 69 ± 94 1 ± 10 30 ± 10 n/a
Maya and Allon
[23] 2006 14
Prospective,
Non-
randomized
Wallstent,
SMART,
Prot´ eg´ e,
Fluency
AVG 48 19 n/a median 2.8
C h a n ,M . R .e t
al. [24] 2008 211 Retrospective SMART AVG 69 25 n/a median 4.4
Current study 2011 50 Prospective,
Observational SMART Both 79 ± 95 1 ± 15 27 ± 16 median 3.8
25 AVF 80 ± 10 65 ± 16 32 ± 21 median 5.2
25 AVG 76 ± 15 28 ± 22 19 ± 17 median 2.9
retrospective [12] and prospective, nonrandomized studies
[14] for dysfunctional AVG salvage therapy. In previous
reports, the 3-, 6-, and 12-month patency rates of metallic
stents were 77–88%, 51–67%, and 20–41%, respectively
(Table 4).
Our results showed that there was no statistical diﬀer-
ent in patency of AVF and AVG, but AVG showed poor
tendency in primary and secondary patency. Incidents of
out-ﬂow stenosis were signiﬁcantly higher in AVF, and in-
stent stenosis were signiﬁcantly higher in AVG. Out-ﬂow
stenoses in AVF might be caused by longer out-ﬂow vein
of forearm AVF, secondary to hemodynamic change or
selection bias because of the small number of patients.
In-stent stenoses in AVG were mainly caused by ingrowth
of neointimal hyperplastic tissue through the mesh of the
metallic stent at the venous-graft anastomotic site. These
data suggest a prevention of in-growth tissue in SMART
stent has potential to improve poor patency in AVG. To
further improve patency and reduce the incidence of luminal
hyperplasia, several authors have explored the use of the
stent-graft, which is a self-expanding nitinol stent covered
in carbon-impregnated expanded polytetraﬂuoroethylene.
The use of stent-grafts or covered stents appears to be
logical to prevent ingrowth of neointimal hyperplastic tissue.
Haskal et al. [15]p e r f o r m e dar a n d o m i z e d ,p r o s p e c t i v e ,
multicenter trial involving 190 patients and clearly indicated
noninferiority extending the patency of AVG cases at 6
months. Further studies are necessary to determine appro-
priate indications for the use of stents in AVG with rapid
recurrence.International Journal of Nephrology 5
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Figure 1: Primary patency rates in AVF and AVG. No signiﬁcant
diﬀerence was observed in the primary patency rates between AVF
and AVG, but patency in AVG showed inferior to AVF.
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Figure 2: Secondary patency rates of SMART stent placement in
AVF and AVG. There was no signiﬁcant diﬀerence in the secondary
patency rates between AVF and AVG, but patency in AVG showed
inferior to AVF.
In this present study, salvage SMART stent placement
provides similar primary patency in previous reports [12,
14, 21–24]( Table 4). The main reason of insuﬃcient patency
was that the patients in this study were selected because
they were basically PTA failures with either elastic lesions or
rapid recurrences. Therefore, a use of SMART stent is only
in selective patients, in whom without stent placement, the
vascular access will be restenotic or abandoned immediately
or in a very short time. But after stent placement, the patency
may be the same or only slightly better than that of regular
cases [4, 10, 11]. These results suggest that there were no or
limitedclinicaladvantageofroutineuseofbaremetallicstent
overangioplastyonly,althoughstentgrafthadrevealedsome
clinicalbeneﬁts.However,ourresultshavecertainlimitations
such as small sample size, a nonrandomized trail performed
atasingleinstitute,withoutappropriatecontrolgroup.Large
randomized, comparative studies are necessary to conﬁrm
the usefulness and appropriate indications stent placement
in hemodialysis patients.
5. Conclusion
SMART stent placement was a safe for salvage angioplasty
in treating recurrent peripheral vascular stenosis, but the
usefulness of SMART stents was limited in a short period of
time despite our eﬀorts to improve patency. Larger studies
are required to determine appropriate indications.
Abbreviation
PTA: Percutaneous transluminal angioplasty,
SMART: Shape memory alloy recoverable
technology
AVF: Arteriovenous ﬁstula
AVG: Arteriovenous graft
DM: Diabetes mellitus.
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